Johnson & Johnson Restricted Cash
Johnson & Johnson (JNJ) had Restricted Cash of $7.70 billion as of 2023-04-02, per its 10-Q filed 2023-04-28.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCash · last filed 2023-04-28
- 2023-04-02: Restricted Cash $7.70B.
- 2023-01-01: Restricted Cash $0.00.
| Period end | Restricted Cash |
|---|---|
| 2023-04-02 | $7.70B 10-Q · filed 2023-04-28 |
| 2023-01-01 | $0.00 10-Q · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |